This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
The investigational menin–MLL inhibitor KO-539 may be active in patients with acute myeloid leukemia: In a phase I trial, the agent induced complete remissions in two patients with relapsed/refractory disease and showed signs of activity in several others.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on December 30, 2020
doi: 10.1158/2159-8290.CD-NB2020-120
AML Prognoses Better with Menin–MLL Inhibitor?
Jump to section
Advertisement